Anti-Mouse CD8 beta Antibody (53-5.8)
Based on 1 Customer Validation
Anti-Mouse CD8 beta Antibody (53-5.8) is an anti-mouse CD8 beta IgG2a monoclonal antibody. Anti-Mouse CD8 beta Antibody (53-5.8) can deplete CD8+ T cells and enhance cytotoxicity. Anti-Mouse CD8 beta Antibody (53-5.8) can be used for research on immunology.
For research use only. We do not sell to patients.
- Purity : 97.95%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Rat IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
CD8 beta
In Vitro
Anti-Mouse CD8 beta Antibody (53-5.8) (0.1-10 μg/mL, 1-2 h) enhances cytotoxicity at low concentrations (0.1 μg/mL) and significantly inhibits killing function at high concentrations (> 1 μg/mL) in OT1 CD8+ T cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Anti-Mouse CD8 beta Antibody (53-5.8) (500 μg, i.p., single dose, on the second day after injecting CD45.1+ OT1 T cells) exhausts CD8+ T cells and changes them to short lived effector cells (SLEC) phenotype with enhanced cytotoxicity in C57BL/6 mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID-beige mice (1 month) induced with Doxycycline (HY-N0565) diet (200 mg/kg)[1]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once weekly after the end of treatment
-
Result:Decreased the number of CD8+ T cells.
Significantly increased the tumor recurrence rate compared to the control group.
-
Animal Model:C57BL/6 mice (5-10 weeks)[2]
-
Dosage:500 μg
-
Administration:Intraperitoneal injection (i.p.), single dose, on the second day after injecting CD45.1+ OT1 T cells.
-
Result:Caused CD8+ T cells to exhibit the SLEC phenotype with enhanced cytotoxicity.
Gene ID
Accession
P10300
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vivo CD8+ T cell depletion; in vitro CD8 blockade; Immunofluorescence
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse CD8 beta Antibody (53-5.8)]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Tsao LC, et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat Commun. 2025 Apr 2;16(1):3167. [Content Brief]
[2]. Cross EW, et al. Anti-CD8 monoclonal antibody-mediated depletion alters the phenotype and behavior of surviving CD8+ T cells. PLoS One. 2019 Feb 8;14(2):e0211446. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)